Perspectum Announces World’s 1st Integrated Imaging Service for Long Covid Is Approved by UK’s MHRA

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

January 14, 2021

The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of CoverScan MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs, developed by Perspectum. With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long COVID”, CoverScan MD quickly and safely provides medical professionals with the information critically needed to assess and evaluate patients.

“I’m thrilled to hear that Coverscan** has been granted approval by MHRA. I cannot stress enough how much myself and a large number of people with Long Covid* have benefitted from Coverscan. For those of us with organ damage, it has accelerated our access to treatment by informing us exactly what organs need to be examined further, while for the rest of us, it has brought us invaluable peace of mind. This is a step in the right direction, and I hope everyone who is misfortunate enough to suffer from Long Covid can benefit from this.”

Lyth Hishmeh, COVERSCAN Study Patient

‘The MHRA authorization of Coverscan is timely. UK experts and NICE are developing a COVID follow up a pathway which provides equitable access and high-quality community-based triage with rapid access to diagnostics and multi-specialty services. We have seen over 800 patients in North London, and it would be very valuable for their clinical care to be able to access COVERSCAN results.’

Dr. Melissa Heightman, Consultant Respiratory Physician, UCL, and Head of North London Long Covid care services

Perspectum’s CoverScan MD technology enables healthcare providers to identify coronavirus-related systemic organ damage through scans of patients’ hearts, lungs, livers, as well as other internal organs, and to assess the impact of SARS-CoV-2 infections. With the use of CoverScan MD, UK doctors will now have a technology to add to the arsenal of tools used to assess and evaluate patients with Long COVID, while at the same time gain a greater understanding of its symptoms and long-term impact on different organ systems.

*Long Covid affects 10-30% of people who have symptomatic infection with Sars-CoV-2 and is defined as symptomatic disease lasting longer than 12 weeks. Patients typically have extreme fatigue, chest pain, breathlessness, muscle aches, and brain fog, but there are many reported symptoms. Many of these patients have organ damage or impairment, and ways of managing this are currently being researched. Patients with Long Covid are often unable to work for long periods of time, posing a significant burden on the economy and public services.

**CoverScan MD is a software suite that provides a comprehensive, one-stop-shop assessment to detect damage in the heart, liver, lungs, kidneys, pancreas, and spleen. This single, quick MRI exam eliminates the need for multiple individual or invasive tests.

Healthcare professionals and patients are then provided with quantitative measurements and accurate information, enabling them to develop personalized treatment plans for the long-term care of patients. MHRA authorization will allow this technology to be made available to UK patients.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.